Tilmann has a PhD in Biochemistry from the Robert-Koch-Institute in Berlin, where he worked on host-pathogen interaction. Afterwards, he joined the laboratory of Giulio Superti-Furga at the Research Center for Molecular Medicine (CeMM) in Vienna to study the innate immune response to viral infection as a post-doctoral fellow. Following that, Tilmann was hired as a Principal Scientist to establish the newly founded biotech company Haplogen which was centered on exploiting haploid human cells for genetic studies. He stayed with Haplogen and, later on, Haplogen Genomics for four years, serving as Head of Research and Chief Scientific Officer. Following the acquisition of Haplogen Genomics by Horizon Discovery, Tilmann became R&D director and, later, Global Head of Innovation. At Horizon, Tilmann lead several teams across sites and was in charge of developing Horizon’s technology portfolio. In January 2018, Tilmann decided to leave Horizon and teamed up with Thomas Moser and Christoph Bock to found Aelian Biotechnology GmbH. At Aelian, Tilmann combines CRISPR screening with single-cell sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes.